Lifeline Technologies

May 17, 2002

Office of Nutritional Products, Labeling and
Dietary Supplements (HFS-800)
Center for Food Safety and Applied Nutrition
Food and Drug Administration
5100 Paint Branch Parkway
College Park, MD 20740-3835

MAY 20 2002

Re: FDA's Response to Lifeline's Notification Dated April 18, 2002

Dear Sir or Madam:

Thank you for your timely response to the above-referenced notification.

To better comply with the requirements of section 403(r)(6) of the Federal Food, Drug, and Cosmetic Act, Lifeline Technologies, Inc. notifies FDA that it will use the following statement:

> "ChoLESStolife lowers cholesterol absorption in the small intestine to help retain already healthy cholesterol levels."

This statutory statement will appear on a dietary supplement, and it is based on the consumption of 875 mg/day of soy stanols, the active ingredient in the tablet(s). This statutory statement will appear with the following product:

ChoLESStolife, a dietary supplement

I certify that the foregoing is complete and accurate, and that Lifeline Technologies, Inc. has substantiation that the statements are truthful and not misleading.

Very truly yours,

Lifeline Technologies
400 Chesterfield Center, Suite 120
Chesterfield, MO 63017

by _____

Curtis A. Spilburg, Ph.D.
President

97S 0162 LET 10115